Ann: Quarterly Activity Report & Appendix 4C, page-35

Striate+ is on the Prescribed List of Medical Devices and Human Tissue products for $251. I'd be surprised if OCC would be getting much less than $150 per unit for sales in Australia. Certainly not $50/unit. Very likely not less than $100. Maybe someone can guess a price for the US find out the actual sale price. Probably not much less than Australian equivalent. Maybe more??
Likely because of the large BH payment upfront the percentage OCC gets of the sales revenue may initially be limited, but increase over time after sales milestones have been reached, but this is just speculation. We'd need to know what was in the agreement with BH.
Remplir up for $1354.
5 million dental implants annually in the US. This is why OCC has flagged it as a US$1bn+ market. Suggests sales price of around US$200+/unit. It remains to be seen if this can be achieved. If we can get a 10% market penetration if Striate+ is as good as OCC suggests, then in a few years(I'm hoping not much more than 5) and making many assumptions that come true OCC may be looking at $100m+ in revenues from Striate+ alone.